Development of a core outcome set for trials investigating the long-term management of bronchiectasis.


Journal

Chronic respiratory disease
ISSN: 1479-9731
Titre abrégé: Chron Respir Dis
Pays: England
ID NLM: 101197408

Informations de publication

Date de publication:
Historique:
pubmed: 4 10 2018
medline: 9 6 2020
entrez: 4 10 2018
Statut: ppublish

Résumé

Heterogeneity in outcomes measured in trials limits accurate comparison of bronchiectasis studies. A core outcome set (COS) is an agreed, standardized set of outcomes that should be measured in trials for specific clinical areas. A COS for bronchiectasis could encourage consistency in future studies. An overview of systematic reviews and qualitative study on outcome selection in bronchiectasis informed an initial list of outcomes. A Delphi panel ( n = 86) rated the importance of each outcome from 1 to 9 in 3 sequential questionnaires, as a means to achieve consensus: 1-3 = 'of limited importance'; 4-6 = 'important, but not critical'; and 7-9 = 'critical'. Outcomes rated 'critical' by ≥70% of the panel were added to the COS. Eighty-two participants responded to the first questionnaire. Attrition between each questionnaire was 5%. After 3 rounds of questioning, 18 outcomes exceeded the threshold for consensus and were included in the COS. This study has achieved consensus on 18 outcomes that should be measured in trials of interventions for bronchiectasis. Selection of the highest ranked outcomes may represent a pragmatic means for comparison. Further research is required to condense the number of outcomes selected and to determine its relevance to interventions.

Identifiants

pubmed: 30278785
doi: 10.1177/1479972318804167
pmc: PMC6301837
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1479972318804167

Références

Qual Life Res. 2010 May;19(4):539-49
pubmed: 20169472
J Clin Pharm Ther. 2001 Feb;26(1):5-14
pubmed: 11286603
Lancet. 2009 Jul 4;374(9683):86-9
pubmed: 19525005
Eur Respir J. 2006 Apr;27(4):822-32
pubmed: 16585091
Eur Respir J. 2016 Sep;48(3):632-47
pubmed: 27288031
Eur Respir J. 2008 Feb;31(2):416-69
pubmed: 18238951
Trials. 2012 Aug 06;13:132
pubmed: 22867278
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
BMC Health Serv Res. 2015 Aug 22;15:342
pubmed: 26297038
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
Cochrane Database Syst Rev. 2015 Aug 13;(8):CD001392
pubmed: 26270620
Cochrane Database Syst Rev. 2015 Jul 14;(7):CD010337
pubmed: 26171905
Trials. 2014 May 13;15:168
pubmed: 24885068
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
Trials. 2017 Apr 12;18(1):175
pubmed: 28403876
Trials. 2007 Nov 26;8:39
pubmed: 18039365
Trials. 2013 Mar 12;14:70
pubmed: 23497540
PLoS Med. 2016 Aug 09;13(8):e1002071
pubmed: 27505051
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Lancet Respir Med. 2016 Dec;4(12):940-941
pubmed: 27890499
Thorax. 2014 May;69(5):428-36
pubmed: 24368713

Auteurs

Maureen Spargo (M)

1 School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland.

Cristín Ryan (C)

2 The School of Pharmacy & Pharmaceutical Sciences, Panoz Institute, Trinity College Dublin, Dublin, Ireland.

Damian Downey (D)

3 Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland.
4 Regional Respiratory Centre, Belfast City Hospital, Belfast, Northern Ireland.

Carmel Hughes (C)

1 School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH